Video: MS Views NOW – Dietary Approaches for MS, Covid updates for those with Multiple Sclerosis, medication information and more
Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews…
Let’s Learn about a New MS Treatment, – with Nurse Practitioner Katrina M. Bawden, MSN, MSCN, NP-C.
Share your comments with us please… Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews…
Stuart Schlossman
Let’s Learn about a New MS Treatment – with Nurse Practitioner Katrina M. Bawden, MSN, MSCN, NP-C.
Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews…
Stuart Schlossman
Off-label DMT Use for Progressive MS May Be as Effective as On-label
by Lindsey Shapiro, PhD | September 7, 2022 ‘Small’ difference in disability worsening at 2 years seen across 5 trials…
Stuart Schlossman
IFN-beta Therapy Found to Help Blood Vessels in Brain Dilate in MS
by Vanda Pinto, PhD | September 30, 2022 DMT restores cerebrovascular reactivity that’s reduced in patients: study Treatment with interferon beta (IFN-beta) —…
Stuart Schlossman
Survival Much Higher for MS Patients Who Take DMTs as Directed: Study
Medication adherence linked to greater survival for US veterans prescribed DMTs by Marisa Wexler, MS | September 23, 2022 The likelihood of survival…
Stuart Schlossman
Novartis to Petition U.S. Supreme Court to Uphold Gilenya Patent
Novartis said it will petition the U.S. Supreme Court to uphold a patent that protects the dosing regimen of Gilenya (fingolimod) that’s approved…
Stuart Schlossman
FDA puts brakes on Sanofi’s $3.7B multiple sclerosis bet, imposing partial hold, over liver injuries
The $3.7 billion centerpiece of Paul Hudson’s R&D strategy for Sanofi has hit a setback. Seeing cases of drug-induced…
Stuart Schlossman
Welcome to the MSAA Ultimate MS Treatment Guide – an online tool to help people with multiple sclerosis
August 2022 MSAA is proud to announce the launch of the Ultimate MS Treatment Guide (MStreatmentguide.org) – an online tool…
Stuart Schlossman
Rituximab Outperforms Tecfidera at Preventing Relapses in Phase 3 Trial
by Marisa Wexler, MS | July 15, 2022 Patients on rituximab MS treatment 5 times less likely to experience relapse…
Stuart Schlossman
